Business
Visionary Holdings Inc. Announces Key Governance Updates, Strategic Pivot to High-End Medical Aesthetics, and Timeline for Annual Report Filing
MARKHAM, Ontario, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (the “Company”), today announced several material corporate developments, including the results of its 2025 Annual General Meeting, the formation of a new leadership team, and a formal strategic shift toward the anti-aging high-end medical aesthetics sector. A copy of the company’s Report on Form-6K is being provided as an exhibit to this press release for reference. New Governance and Leadership TeamFollowing the Annual
About this update from Visionary Holdings Inc.
[{"type":"text","content":"MARKHAM, Ontario, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (the “Company”), today announced several material corporate developments, including the results of its 2025 Annual General Meeting, the formation of a new leadership team, and a formal strategic shift toward the anti-aging high-end medical aesthetics sector. A copy of the company’s Report on Form-6K is being provided as an exhibit to this press release for reference.","length":446,"tagName":"p"},{"type":"text","content":"New Governance and Leadership TeamFollowing the Annual General Meeting held on October 29, 2025, a new nine-member Board of Directors was elected. The Board subsequently appointed a seasoned executive team to lead the Company’s next phase of growth: Executive Leadership: Mr. Xiyong Hou serves as Chief Executive Officer, supported by Mr. Jun Huang as Co-CEO, Mr. Robert Jay Lees as Chief Operating Officer, and Ms. Katy Liu as Chief Financial Officer. Board Leadership: Mr. William T. Chai has been elected Chairman of the Board, with Mr. Donald M. Kealey serving as Vice Chairman. Audit and Compliance: Assentsure PAC has been reappointed as the Company’s auditor for the 2025-2026 fiscal years.","length":701,"tagName":"p"},{"type":"text","content":"Strategic Transformation into Medical AestheticsVisionary Holdings has successfully completed a strategic transformation, establishing a core business focus on anti-aging high-end medical aesthetics, with its traditional education business now serving as a supplementary division. The Company is prioritizing global technology research and development (R&D) and market expansion within this high-growth track. Key milestones in this transformation include two major partnerships established in September 2025:Global R&D Partnership: A cooperation agreement with Jiangsu Yike Regenerative Medicine Technology Co., Ltd. to jointly develop and market medical aesthetics products worldwide. North American Health Center: A joint venture with Anhui Weikang Kangling Medical Technology Co., Ltd. to build an "Anti-Aging High-End Medical Aesthetics and Health Center" at the Company’s property in Toronto, Canada.","length":928,"tagName":"p"},{"type":"text","content":"Financial Reporting UpdateThe Company is pleased to report that the draft of its Annual Report for the fiscal year ended March 31, 2025 ...